Taltz (ixekizumab) is an Eli Lilly biologic in the interleukin-17A class, approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. Unlike its closest competitor it comes in exactly one form, a self-injected autoinjector or prefilled syringe, and it moves through a specialty pharmacy rather than a clinic.
That makes Taltz simpler to price than most specialty biologics and, unfortunately, harder to discount. There is no infusion channel to negotiate, no biosimilar to shop against, and no manufacturer cash-pay platform. Every figure below was verified on September 4, 2026.
What Does Taltz Cost Without Insurance?
| Service/Type | Low | Average | High |
|---|---|---|---|
| One 80 mg autoinjector or syringe (one monthly dose) | $7,374 | $7,456 | $7,625 |
| Two-pack of autoinjectors | $14,872 | $14,903 | $15,249 |
| Three-pack of autoinjectors | $22,165 | $22,351 | $22,874 |
| First three months of psoriasis treatment (8 pens) | $58,988 | $59,645 | $60,997 |
| Maintenance year (13 doses) | $95,856 | $96,923 | $99,120 |
Eli Lilly publishes the number itself. Its pricing page states that the list price of Taltz is $7,624.59 per individual pen, footnoted to wholesale acquisition cost data from AnalySource accessed on January 1, 2026. The same page tells uninsured readers, in Lilly’s own words, that if you do not have prescription drug coverage you can expect to pay close to the list price plus any additional pharmacy charges.
Two independent datasets confirm the shape of that figure. Drugs.com quotes a cash price of $7,455.60 for one 80 mg/mL autoinjector or prefilled syringe. In the CMS National Average Drug Acquisition Cost file effective August 19, 2026, the single autoinjector is $7,373.54, the three-pack works out to $7,388.22 per pen, and the prefilled syringe is $7,402.07.
Medicare Part D data adds a fourth read from a different direction. In 2024, the most recent full year of claims data, Part D paid an average of $6,734.68 per dosage unit for the Taltz autoinjector across 73,919 claims, and an average of $7,636.35 per prescription claim. Claims are not month-normalized, so read that as a per-prescription figure rather than a monthly one.
What Drives the Price
The loading schedule, not the maintenance dose
FDA labeling for adult plaque psoriasis calls for 160 mg (two 80 mg injections) at week 0, then 80 mg at weeks 2, 4, 6, 8, 10 and 12, then 80 mg every 4 weeks. That is 8 pens in the first three months against 3 in a typical later quarter. Lilly states the same thing on its pricing page.
Psoriatic arthritis and ankylosing spondylitis are cheaper to start: 160 mg at week 0 then 80 mg every 4 weeks, so 4 pens in the first quarter. Non-radiographic axial spondyloarthritis has no loading dose at all, just 80 mg every 4 weeks from the start. Ask which schedule applies to you before you budget.
Strength does not change the price
Taltz is sold in 80 mg, 40 mg and 20 mg presentations, the smaller two for pediatric patients. On Drugs.com, all three carry the same $7,455.60 cash price. A 20 mg syringe costs what an 80 mg autoinjector costs, which means the per-milligram price for a small child is four times higher than for an adult.
No biosimilar, no generic, no competition on the molecule
As of September 4, 2026, FDA’s Drugs@FDA database returns exactly one ixekizumab application, BLA 125521, held by Eli Lilly and Company. FDA’s National Drug Code directory, last updated September 2, 2026, lists only Lilly, Eli Lilly Kinsale and Patheon Manufacturing Services as labelers, all of which are Lilly or its contract manufacturers.
That absence shows up at retail. Cost Plus Drugs, which does stock adalimumab and ustekinumab biosimilars in its 2,496-product catalog, carries no ixekizumab and no secukinumab at all. The usual cash-pharmacy tactic simply has nothing to sell you here.
Specialty distribution removes the usual discount tools
Taltz is a refrigerated biologic dispensed through specialty pharmacies. Discount cards are built for retail generics and do essentially nothing at this price point, and the pharmacy-shopping strategies that work for a $40 prescription do not transfer. The variation you see across sources, roughly $250 from lowest to highest, is under 4 percent.
Cash Price vs. Insurance
There is no manufacturer cash-pay channel for Taltz. Its closest competitor has one: Novartis sells Cosentyx directly to cash-paying patients at roughly half of list through a direct-to-patient platform launched in November 2025. Lilly runs self-pay pricing through LillyDirect on other products, but Taltz appears on neither its self-pay pages nor its savings pages as a cash offer, and Lilly’s own pricing page tells uninsured readers to expect to pay close to list. For Taltz, cash means list.
The Taltz Savings Card is real and generous, and it is closed to you if you are uninsured. Lilly’s posted eligibility criteria require that you be enrolled in a commercial drug insurance plan and that you not be enrolled in any state, federal or government funded healthcare program, including Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA or TRICARE.
There are two versions. If your commercial plan covers Taltz you can pay as little as $5 for a one-month fill, with annual savings capped at $10,600 and a maximum of 14 fills per calendar year. If you have commercial insurance that does not cover Taltz, you can pay as little as $25 per month, but that version requires a prior authorization before the first fill and an appeal or medical exception before the fifth. Either way you need a commercial plan to exist.
Two more limits worth recording. The card must be first used no later than December 31, 2026, and savings end on December 31, 2028 or 24 months after first use, whichever comes first. Card savings are not valid for Massachusetts residents if an AB-rated generic equivalent is available or for California residents if an FDA-approved therapeutic equivalent is available.
How to Pay Less
Apply to Lilly Cares first, because it is free drug rather than a discount. The Lilly Cares Foundation lists Taltz as a Group 3 medication, open to patients who have no insurance, or Medicare Part D, or Medicare Part B without supplemental coverage, with household adjusted gross income at or below 500% of the federal poverty level. For 2026 that ceiling is $79,800 for one person, $108,200 for two, $136,600 for three and $165,000 for four. Those are unusually high thresholds for a patient assistance program.
Watch the alternate funding trap. Lilly Cares explicitly excludes patients whose employer or plan requires them to apply as a condition of coverage, a practice known as an alternate funding program. If a third party is pushing you toward the application, say so, because applying through them can disqualify you.
Do not waste time on discount cards. At roughly $7,400 a dose, a coupon card that shaves a few dollars off retail changes nothing. Our comparison of GoodRx and SingleCare explains where those tools actually help, and a specialty biologic is not it.
If a bill has already landed, treat it as negotiable. Specialty pharmacy invoices and any clinic charges attached to your care follow the same rules as any other medical bill. Start with an itemized statement and work through our guide to negotiating medical bills.
Check the prescribing hospital or health system for financial assistance. If your rheumatology or dermatology care runs through a nonprofit hospital, its written financial assistance policy may cover the office visits and labs even when it cannot cover the drug. Our hospital charity care guide covers how to ask and what documentation to bring.
Compare inside the class before you settle. Taltz and Cosentyx are both IL-17A inhibitors at nearly identical list prices, but only one of them has a manufacturer cash channel. Skyrizi and Tremfya target IL-23 with longer dosing intervals, and Humira now faces biosimilar competition that Taltz does not. Our fair price tool can benchmark a quote you have been given.
The Bottom Line
At $7,374 to $7,625 a dose, Taltz is priced almost exactly where its class competitor sits, and the cash-paying patient has fewer moves available than on any other drug in the category. There is no biosimilar, no cash-pay platform, no Cost Plus listing and a savings card whose terms rule you out.
That leaves Lilly Cares as the single most valuable route for an uninsured patient, and its 500% of federal poverty level income ceiling means a lot more people qualify than assume they do. Apply before you pay anything close to list. All figures here are a September 2026 snapshot, and the savings card enrollment deadline of December 31, 2026 is the nearest thing to a hard date on this page.